UMN, Astellas Agree on Termination of Joint Flu Vaccine Programs

March 13, 2017
Japanese biotech startup UMN Pharma said on March 10 that the company and Astellas Pharma have reached a final agreement to terminate their joint programs on cell culture-based influenza vaccines. The announcement comes after Astellas said in January that it...read more